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Isolated regional nodal metastasis in giant cell tumor of the bone: Case report and review of literature
Dear Editor, Giant cell tumors (GCTs) of the bone are benign osteolytic tumor commonly occurring in the third to fourth decades with distal femur being the most common site. [1] They form 5% of the primary skeletal tumors. [2] Metastasis though uncommon is usually seen with recurrences. Curettage with intralesional adjuvant therapy with polymethylmethacrylate, liquid nitrogen, and bone graft has been successfully used to reduce recurrences while preserving function. [3] The management of metastasis is still debatable due to the scarcity of literature.
A 47-year-old female who was diagnosed to have GCT of the left radius for which she underwent left distal radius curettage with bone grafting. After 1 year of disease-free interval (DFI), she developed local recurrence and underwent en bloc resection of radius with reconstruction using nonvascularized fibula graft with plating. She developed local recurrence in the soft tissue in the next 2 years which was managed by wide local excisions. After a DFI of 1 year, she presented with an enlarged mobile epitrochlear node, fine-needle aspiration cytology of which was suggestive of GCT. Computed tomography of the chest showed no pulmonary metastasis. The patient was discussed in multispecialty board and she underwent epitrochlear nodal dissection. The final histopathology showed five nodes, with one node showing metastatic GCT. There was no perinodal spread. Figures 1 and 2 show the presence of tumor within the lymph nodes. She is on regular follow-up for 1 year and has shown no sign of recurrence.
GCT is characterized by scattered multinucleate giant cells among mononuclear stromal cells, together imparting a syncytium-like appearance causing a typical radiolucent lytic shadow on X-ray. [4] The tumor is known for its propensity for local recurrences which are generally amenable to wide excisions. The potential for metastatic spread was first reported by Jaffe et al. in 1940. [5] Distant metastasis is seen in 2%-3% of cases with the lungs being the most common site of distant metastasis and the incidence of pulmonary metastasis varies from 4% to 11% in the literature. [6] Other uncommon sites being the bone, skin, soft tissue, breast, and endobronchial tree have also been reported. [7] Lymph nodal involvement is very rare in GCT and only 13 cases have been reported in the English literature. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Table 1 lists the cases of GCT with lymph node involvement. Dyke, in 1931, reported the presence of GCT in lymph nodes in a case with extensive metastatic disease. [8] Since then, majority have reported mediastinal and para-aortic nodal involvement. Only five have reported regional lymph node involvement, of which two were associated with pulmonary metastasis. [7, [9] [10] [11] [12] Isolated regional node involvement as seen in our case has been reported previously only in three cases. [9] [10] [11] Budzilovich et al. reported the first regional nodal involvement in 1963. [9] Present et al., in 1986, reported a GCT metastasizing to regional lymph node; however, it spread to lungs after a year. [10] In another case reported by Aftab and Umar, there was axillary nodal spread from GCT of the distal humerus without pulmonary involvement. [11] In one of the largest reviews from a tertiary care center, Viswanathan and Jambhekar retrospectively evaluated 470 patients of GCTs, of which 24 had distant metastasis and only one patient had regional lymph node metastasis to inguinal lymph node. In their patient, the primary site was femur and there were multiple lung metastasis along with lymph node metastasis. The authors concluded that there was no association between clinicopathological variables and the development of metastasis. [12] The mechanism of pulmonary metastasis has been speculated to be tumor emboli either upfront or during the time of curettage. Lymphatic spread can also be explained similarly by the multiple surgeries performed previously for our patient.
Metastatic GCT has been successfully treated with complete resection of primary and the metastasis. Pulmonary metastatectomy has been routinely performed in resectable patients, with similar principle applied for lymph node metastasis also. All four cases with regional lymph node metastasis have been managed with surgical resection. Connell et al. successfully managed a patient with excision of primary patellar GCT along with excision of posterior mediastinal nodal mass. [13] Another similar case of GCT of the patella with pulmonary and nodal metastasis treated with metastasectomy. [7] Alternate treatments for unresectable disease have also been attempted with limited success. Lewis et al., in 1996 , reported a case of distal radius GCT with mediastinal node metastasis. They used high dose steroids to downsize the tumor followed by resection of the mediastinal mass. [14] There are isolated cases where chemotherapy and radiotherapy have been utilized with varied success rates. [18] In the absence of literature, no definitive recommendation can be made.
In the present case, an upfront incomplete surgery followed by multiple recurrences with repeated surgeries would have led to tumor emboli spreading through the lymphatics. The patient was successfully managed by lymph node dissection. The implication of lymph node and distant spread in malignant GCT is not as worse compared to other malignancies and hence should be treated with curative intent if completely resectable.
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There are no conflicts of interest. Qureshi et al. [7] Patella Wide excision (patellectomy)
Kanuj Malik, Anand Raja, Sundersingh Shirley 1

Recurrent Regional (inguinal nodes) Lungs Surgical resection
Dyke [8] Patella Amputation Recurrent Distant (mediastinal and peritoneal nodes)
Lungs, spine None
Budzilovich et al. [9] Femur Curettage with bone grafting Recurrent Regional (popliteal nodes) None Surgical resection
Present et al. [10] Femur Wide excision Recurrent Regional None Surgical resection Aftab and Umar [11] Distal humerus and proximal ulna
Wide excision Primary Regional (axillary nodes) None Surgical resection Viswanathan and Jambhekar [12] Femur Amputation Recurrent Regional (inguinal) Lung Surgical resection
Connell et al. [13] Patella Wide excision (patellectomy)
Recurrent Distant (mediastinal nodes) None
Chemotherapy f/b surgical resection Rock et al. [15] Tibia Curettage and bone grafting
Recurrent Distant (mediastinal nodes) Lungs Chemotherapy
Kay et al. [16] Tibia Curettage, phenol application and bone grafting
Recurrent Distant (mediastinal nodes) Lungs None
Lewis et al. [14] Radius Curettage with bone grafting
Recurrent Distant (mediastinal nodes) None
Steroid f/b surgical resection Goldenberg et al. [17] NA NA Recurrent Distant (mediastinal nodes) Lungs NA Vanel et al. [18] Fibula Not treated Primary Distant (mediastinal node) None Radiotherapy Sung et al. [19] NA NA Recurrent Distant (mediastinal nodes) None NA Present case Radius Curettage with bone grafting
Recurrent Regional (epitrochlear) None Surgical resection
NA=Not available, f/b : followed by All analyses were performed using SPSS Statistics for Windows software, version 20.0 (SPSS, Chicago, IL). was used for analysis. Response rate, progression-free survival (PFS), and overall survival were calculated. Response rate was calculated for the best response to treatment. PFS was calculated from starting lorlatinib to events of disease progression, death without disease progression, and change in treatment other than disease progression. Overall survival was calculated from the date of starting lorlatinib to the date of death and separately overall survival was also calculated from the date of diagnosis to the date of death. Tables 1 and 2 Dear Editor, Lung cancer treatment is rapidly evolving and an excellent example of precision medicine. Outcome of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) has improved significantly with recent report showing survival of 56% at 4 years. [1] This has been possible due to availability of effective sequential treatment. One of the important drugs has been lorlatinib. This has found to be effective in second line and beyond setting after crizotinib. [2] There has been no data from India regarding its safety and efficacy. We retrospectively analyzed the data of patients receiving lorlatinib in our hospital. Patients diagnosed with ALK-positive advanced NSCLC who have received lorlatinib between January 2018 and September 2019 who have progressed on crizotinib were included. Lorlatinib was administered orally in a tablet form at a starting dose of 100 mg once daily continuously in 21-day cycles. 
